Preferred Name |
Atezolizumab |
|
Synonyms |
Immunoglobulin G1, Anti-(human CD Antigen cd274) (Human Monoclonal MPDL3280A Heavy Chain), Disulfide with Human Monoclonal MPDL3280A Kappa-chain, Dimer Atezolizumab ATEZOLIZUMAB MPDL 3280A MPDL 328OA MPDL-3280A MPDL3280A MPDL328OA RG7446 RO5541267 Tecentriq |
|
Definitions |
A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1; PDCD1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 (CD80) expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of atezolizumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). |
|
ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106250 |
|
Accepted_Therapeutic_Use_For |
the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained >= 50% of tumor cells [TC >= 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering >= 10% of the tumor area [IC >= 10%]), with no EGFR or ALK genomic tumor aberrations. metastatic non-small cell lung cancer (NSCLC); locally advanced or metastatic urothelial carcinoma; extensive-stage small cell lung cancer (ES-SCLC) |
|
CAS_Registry |
1380723-44-3 |
|
code |
C106250 |
|
Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
Contributing_Source |
CTRP FDA GDC HemOnc |
|
DEFINITION |
A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1; PDCD1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 (CD80) expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of atezolizumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). |
|
Display_Name |
Atezolizumab |
|
FDA_UNII_Code |
52CMI0WC3Y |
|
FULL_SYN |
Immunoglobulin G1, Anti-(human CD Antigen cd274) (Human Monoclonal MPDL3280A Heavy Chain), Disulfide with Human Monoclonal MPDL3280A Kappa-chain, Dimer Atezolizumab ATEZOLIZUMAB MPDL 3280A MPDL 328OA MPDL-3280A MPDL3280A MPDL328OA RG7446 RO5541267 Tecentriq |
|
Has_Target | ||
Is_Value_For_GDC_Property | ||
label |
Atezolizumab |
|
Maps_To |
Atezolizumab |
|
NCI_Drug_Dictionary_ID |
702758 |
|
PDQ_Closed_Trial_Search_ID |
702758 |
|
PDQ_Open_Trial_Search_ID |
702758 |
|
Preferred_Name |
Atezolizumab |
|
prefixIRI |
Thesaurus:C106250 |
|
Semantic_Type |
Amino Acid, Peptide, or Protein Pharmacologic Substance |
|
UMLS_CUI |
C3827082 |
|
subClassOf |